New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
09:23 EDTSYK, STJ, BSX, IART, EW, ZMH, NUVA, COVBarclays medical supplies/devices analysts hold analyst/industry conference call
Medical Supplies & Devices Analysts provide a review of the recently held Barclay's Medtech Symposium on an Analyst/Industry conference call. Relevant companies COV, BSX, STJ, MDT, EW, NUVA, IART, SYK and ZMH may be discussed on the Analyst/Industry conference call to be held on April 15 at 10:30 am.
News For BSX;COV;EW;STJ;NUVA;IART;SYK;ZMH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 15, 2015
14:20 EDTSTJSt. Jude Medical reports positive results from CardioMEMS HF System
Subscribe for More Information
14:01 EDTSTJSt. Jude Medical reports positive results from Allure Quadra CRT-P System
St. Jude Medical announced the presentation of important data supporting the first and only quadripolar cardiac resynchronization therapy pacemaker system in the U.S., during the Heart Rhythm Society's 36th annual scientific sessions. The Allure Quadra CRT-P system, with the Quartet Quadripolar LV Lead is associated with a 63% reduction in the need to replace the lead or deactivate CRT following implant. Quadripolar LV pacing using SJM quadripolar CRT-Ds or CRT-Ps and an SJM quadripolar lead provides physicians with multiple pacing options to avoid phrenic nerve stimulation and allow for optimal treatment delivery without the need to replace or deactivate the therapy. An analysis evaluating more than 3,000 patients implanted with a CRT-P (1,325 with a quadripolar lead vs. 1,930 with a bipolar lead) looked at whether the known decreased need to replace or deactivate LV leads associated with SJM quadripolar CRT-Ds and the Quartet LV lead also extends to St. Jude Medical quadripolar CRT-Ps. The retrospective data analysis was presented in a session titled Quadripolar Leads are Associated with Fewer LV Lead Replacements and Deactivations in CRT-P Patients by Dr. Mintu P. Turakhia, who led the investigation. The data show that patients with the Quartet LV lead were 63% less likely to undergo lead replacement or deactivation of CRT compared to the patients with bipolar leads.
10:29 EDTSYK, BSXAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:31 EDTBSXAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
08:45 EDTSTJSt. Jude Medical management to meet with Leerink
Subscribe for More Information
08:41 EDTSTJSt. Jude Medical management to meet with Leerink
Subscribe for More Information
May 14, 2015
13:58 EDTNUVANuVasive initiated with a Market Perform at Northland
Target $46.
13:55 EDTZMHZimmer initiated with an Outperform at Northland
Subscribe for More Information
13:54 EDTSYKStryker initiated with an Outperform at Northland
Subscribe for More Information
09:41 EDTSTJ, BSXLeerink medical devices analyst holds a cardiology luncheon meeting
Subscribe for More Information
08:45 EDTZMHZimmer has a conference call hosted by JPMorgan
Subscribe for More Information
May 13, 2015
08:08 EDTSTJSt. Jude Medical receives CE Mark approval of Ellipse expanded labeling
Subscribe for More Information
07:31 EDTBSX, SYK, STJHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
May 12, 2015
11:43 EDTSYKStryker backs FY15 organic revenue growth of 5%-6%
Subscribe for More Information
10:01 EDTEWOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:35 EDTSTJBofA/Merrill to hold a conference
Subscribe for More Information
06:48 EDTEWEdwards Lifesciences upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Edwards Lifesciences to Overweight following the 15% selloff since mid-March. The firm says its confidence in the conversion of the surgical valve replacement market to transcatheter replacement increased significantly at this year's ACC. It adds that its recent field work indicates the TAVR market has accelerated post-ACC. JPMorgan raised its price target for shares to $155 from $147.
06:35 EDTEWEdwards Lifesciences upgraded to Overweight from Neutral at JPMorgan
05:23 EDTBSXNevro announces filing of petitions for inter partes review by Boston Scientific
Subscribe for More Information
May 11, 2015
17:00 EDTIARTStuart Essig reports 4.5% stake in Integra LifeSciences
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use